About Ian Clark
Ian Clark is a director at Guardant Health.
Form D filings name Ian Clark as a director at Kyverna Therapeutics.
Ian Clark reports to the SEC as a director or officer of 14 public companies, including Olema Pharmaceuticals (OLMA), Corvus Pharmaceuticals (CRVS) and Biomarin Pharmaceutical (BMRN).
Ian Clark first appears on SEC filings in 2006.
Experience
This experience comes from SEC filings. The years are when the filings name Ian Clark in the role, so the role may have started earlier or lasted longer.
GI
Guardant Health, Inc.
Director
2018 – 2026 · Public company (GH)
OI
Olema Pharmaceuticals, Inc.
Director
2020 – 2026 · Public company (OLMA)
CI
Corvus Pharmaceuticals, Inc.
Director
2017 – 2026 · Public company (CRVS)
BI
Biomarin Pharmaceutical Inc.
Director
2025 – 2026 · Public company (BMRN)
TL
Takeda Pharmaceutical Co. Ltd.
Director
2026 · Public company (TAK)
GI
GoodRx Holdings, Inc.
Director
2024 – 2025 · Public company (GDRX)
TI
Tectonic Therapeutic, Inc.
Director
2018 – 2023 · Public company (TECX)
AI
Agios Pharmaceuticals, Inc.
Director
2017 – 2022 · Public company (AGIO)
FI
Forty Seven, Inc.
Director
2018 – 2020 · Public company (FTSV)
KI
Kite Pharma, Inc.
Director
2017 · Public company (KITE)
TI
TerraVia Holdings, Inc.
Director
2011 – 2017 · Public company (TVIA)
DC
Dendreon Corp.
Board of Director
2009 – 2010 · Public company (DNDNQ)
GI
Genentech Inc.
Evp-commercial
2006 – 2009 · Public company (DNA)
Key Colleagues at Startups
The people Ian Clark works with at each company, as listed on that company's latest Form D.
Kyverna Therapeutics, Inc. · Form D, Nov 7, 2023
BK
Brian Kotzin
Director
RJ
Ryan Jones
Chief Financial Officer
KW
Karen Walker
Executive officer
PM
Peter Maag
Executive officer and director
JC
James Chung
Executive officer
DS
Dan Spiegelman
Director
BS
Beth Spiegelman
Director
FC
Fred Cohen
Director
SL
Steve Liapis
Director
DB
Dominic Borie
Executive officer